Table 1.
Anti-GD2 antibodies
| Antibody | Description | Key aspects | References |
|---|---|---|---|
|
| |||
| 3F8 | Mouse IgG3 antibody | Large experience as single agent and in combinations | 11, 12, 21, 22 |
| 126 | Mouse IgM | Used to purge bone marrow and peripheral blood stem cells | 17, 18, 27, 104, 132 |
| 14.G2a | Mouse IgG2a antibody | Used to generate ch14.18 | 39 |
| ME36.1 | Mouse antibody class switched to IgG1 and IgG2a | Cross-reacts with GD3 | 7 |
| 14.18 | Mouse IgG3 antibody | Lower ADCC than 14.G2a | 39 |
| L72 | Fully human IgM | Produced by EBV-transformed cell lines | 133 |
| ch14.18 (dinutuximab) | Mouse human chimeric I gG1 antibody produced in SP2/0 | FDA- and EMA-approved indication for NB | 5, 12, 14, 134 |
| ch14.18/CHO (dinutuximab beta) | Mouse human chimeric antibody produced in CHO cells | EMA-approved indication for NB | 15, 32–34 |
| hu14.18-IL2 | Humanized 14.18 antibody fused with IL-2 | Clinical trials of fusion version with IL-2 | 48, 50 |
| hu14.18K322A | Point mutation made in hu14.18 | Made to reduce complement activation | 13, 38 |
| hu3F8 | Humanized 3F8 antibody | Less complement activation than 3F8 | 39, 135 |
| 8B6 | Monoclonal antibody that binds to O-acetyl-GD2 | Proposed to reduce pain | 7, 39 |
Abbreviations: ADCC, antibody-dependent cellular cytotoxicity; EBV, Epstein-Barr Virus; EMA, European Medicines Agency; FDA, Food and Drug Administration; NB, neuroblastoma.